Long before the coronavirus-2019 (COVID-19) pandemic began, four research groups—two at universities and two at biotechnology companies—were preparing for it by tackling a seemingly outlandish challenge proffered by the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense: find a stopgap defense against emerging pathogens, so people would have protection until a longer-term solution, notably a vaccine, became available. Under the challenge, called the Pandemic Prevention Platform (P3) program, the groups were to develop technology that would generate a treatment within 60 days of a virus being identified, and have that treatment begin to confer protection within three days of it being administered [1].

中文翻译：

---

开发抗体防御

早在 2019 年冠状病毒 (COVID-19) 大流行开始之前，四个研究小组——两个在大学，两个在生物技术公司——就准备应对美国国防高级研究计划局 (DARPA) 提出的一项看似古怪的挑战。美国国防部：找到针对新出现的病原体的权宜之计，这样人们就可以得到保护，直到出现更长期的解决方案，尤其是疫苗。在被称为大流行预防平台 (P3) 计划的挑战下，这些小组将开发可在确定病毒后 60 天内产生治疗的技术，并让该治疗在给药后三天内开始提供保护。 1]。